Payment overview · 2025
General Payments
$380.18
20 reported records · 10 companies
Healthcare provider profile · identity verified
Amanda R Lowe, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PIKEVILLE, KY · NPI 1225357619
Verified facts
What the public records show
CMS Open Payments records show Amanda R Lowe, D.O. received $380.18 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.69 | 22.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.15 | 17.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.23 | 16.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.59 | 12.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.68 | 7.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.55 | 5.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.19 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.30 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.28 | 4.5% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.52 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $380.18 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.69 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.23 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.95 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.59 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.22 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.68 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
142 | 29 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 524 | 104 |
| Omeprazole | Omeprazole | 448 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 88 |
| Metformin Hcl | Metformin Hcl | 365 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 280 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 56 |
| Furosemide | Furosemide | 230 | 58 |
| Ibuprofen | Ibuprofen | 228 | 63 |
| Gabapentin | Gabapentin | 225 | 39 |
| Montelukast Sodium | Montelukast Sodium | 218 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 192 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 36 |
| Potassium Chloride | Potassium Chloride | 165 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 151 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 151 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 32 |
| Farxiga | Dapagliflozin Propanediol | 142 | 29 |
| Allopurinol | Allopurinol | 138 | 26 |
| Losartan Potassium | Losartan Potassium | 130 | 29 |
| Sertraline Hcl | Sertraline Hcl | 128 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 125 | 33 |
| Sucralfate | Sucralfate | 125 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 125 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 26 |
| Ozempic | Semaglutide | 120 | 22 |
| Meloxicam | Meloxicam | 117 | 29 |
| Methylprednisolone | Methylprednisolone | 115 | 85 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 27 |
| Trazodone Hcl | Trazodone Hcl | 110 | 23 |
| Ezetimibe | Ezetimibe | 104 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 102 | 19 |
| Mounjaro | Tirzepatide | 101 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 94 | 16 |
| Simvastatin | Simvastatin | 94 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 16 |
| Glipizide | Glipizide | 89 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 80 | 14 |
| Tramadol Hcl | Tramadol Hcl | 74 | 14 |
| Jardiance | Empagliflozin | 72 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 14 |
| Alendronate Sodium | Alendronate Sodium | 64 | 11 |
| Kerendia | Finerenone | 63 | suppressed |
| Tradjenta | Linagliptin | 63 | 12 |
| Famotidine | Famotidine | 62 | 17 |
| Carvedilol | Carvedilol | 59 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 11 |
| Azithromycin | Azithromycin | 52 | 37 |
| Januvia | Sitagliptin Phosphate | 52 | 12 |
| Fenofibrate | Fenofibrate | 50 | 11 |
| Glipizide Er | Glipizide | 50 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 12 |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Primidone | Primidone | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Verapamil Er | Verapamil Hcl | 44 | 12 |
| Nystatin | Nystatin | 43 | 18 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 12 |
| Atenolol | Atenolol | 39 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Naproxen | Naproxen | 39 | 12 |
| Dutasteride | Dutasteride | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Celecoxib | Celecoxib | 32 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | 11 |
| Eliquis | Apixaban | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 22 |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 22 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | 15 |
| Mupirocin | Mupirocin | 24 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Cefdinir | Cefdinir | 20 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 11 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Prednisone | Prednisone | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Byetta | Exenatide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $380.18 · 20 records | ABBVIE INC. | AIRSUPRA, AREXVY, CAPLYTA, COLLAGENASE SANTYL, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, NURTEC ODT, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error